TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02932306
Drug: IDP-121 Vehicle Lotion
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: IDP-121 vehicle lotion will be applied as per the instructions provided by the investigational center staff.
Study: NCT02585934
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: once daily, oral, pill manufactured to match RVT-101 35 mg tablet
Study: NCT03612557
Drug: penicillin G benzathine
Normalized name: Penicillin G Benzathine
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 million units (IM) of benzathine benzylpenicillin
Study: NCT03557424
Drug: Polyglucosamine Glucomannan normal dose (Verum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Verum three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study: NCT03557424
Drug: Polyglucosamine Glucomannan high dose (Verum)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Verum 2 three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study: NCT03557424
Drug: Placebo Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients received Placebo three times a day for 65 days. The patients had to dissolve the powder included in one sachet in 250 ml water and drink the solution 15 minutes before each meal. It was recorded whether the patients changed their Lifestyle (their dietary habits and doing sports) during the study.
Study: NCT02674906
Drug: Heparin
Normalized name: Heparin
DrugBank: Heparin (DB01109)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: use of heparin as anticoagulant after blood salvage during cardiac surgery
Study: NCT00893737
Drug: sumatriptan succinate 85 mg/naproxen sodium 500 mg (Treximet)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treximet 1 tablet as soon as the patient has headache indicative of migraine. May be repeated between 2 and 24 hours post-treatment for persistent or recurring headache. Subjects should not take more than 2 Treximet tablets in 24 hours.
Study: NCT00928707
Drug: GIVINOSTAT (ITF2357) 50 mg o.d. + MTD Hydroxyurea
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg o.d. of GIVINOSTAT + MTD of HU monotherapy
Study: NCT01996683
Drug: desferal, ferriprox, blood transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Deferiprone (75-100 mg/kg/d) and deferoxamine (20-60 mg/kg/d) aimed at achieving normal body iron stores in poly-transfued arm1.~Arm 2 will only recieve blood transfusion with no chelation
Study: NCT00357123
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 20 mg 10 days daily since abdominal sepsis diagnosis
Study: NCT01906450
Drug: Scaling and root planing plus Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Single session of scaling and root planning using ultrasonic device. Azithromycin tablets 500mg, 1 tablet every 24 hours for 5 days
Study: NCT01906450
Drug: Scaling and root planing plus placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single session of scaling and root planning placebo tablets 500mg, 1 tablet every 24 hours for 3 days
Study: NCT03584724
Drug: Norflo Oro
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norflo Oro is highly bioavailable curcumin complexed into phytosomes
Study: NCT03584724
Drug: Placebo for Norflo Oro
Normalized name: Oro Clense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo consist of look-alike single foil pouches without active ingredient of Norflo.
Study: NCT02988024
Drug: LY03005
Approvals — FDA: no, EMA: no, PMDA: no
Description: LY03005
Study: NCT02344719
Drug: Taurin 6g per day per oral for 28 days
Normalized name: Taurine
DrugBank: Taurine (DB01956)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Taurin 6g per day per oral for 28 days
Study: NCT02344719
Drug: Placebo 6g per day per oral for 28 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Taurin 6g per day per oral for 28 days
Study: NCT03628625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Folic acid for 3 days
Study: NCT00459901
Drug: Erlotinib and capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01381666
Drug: INS316 solution for inhalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: inhalation via nebulizer given for 2 doses for 60 minutes each
Study: NCT01056042
Drug: ethinyl estradiol 30 micrograms, gestodene 75 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: one tablet orally, everyday
Study: NCT04236323
Drug: Not used remifentanil infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: Remifentanil is not used during operation
Study: NCT03207867
Drug: NIR178
Approvals — FDA: no, EMA: no, PMDA: no
Description: NIR178, a new, non-xanthine based compound, is a potent oral adenosine A2a receptor against antagonist being developed by Novartis.~NIR178 was administered orally twice daily (BID) as a capsule (Part 1, Part 2 and Japanese safety run-in) and as a film-coated table (Part 3). There were up to 3 dose levels assessed: 80, 160 and 240 mg. Three alternative dosing schedules were evaluated: continuous (Part 1, Part 2, Part 3, Japanese safety run-in), 2 weeks on/2 weeks off (Part 2) and 1 week on/1 week off (Part 2).~Each cycle consisted of 28 days.
Study: NCT03574948
Drug: Placebo oral capsule
Normalized name: Placebo Oral Capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 8 weeks placebo (2 x 1 caps per day)
Study: NCT02528513
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl is used with bolus dosage of 1-2ug/kg and maintenance dosage of 1-2ug/kg/h, with the dosage adjusted to critical care pain observation tool（CPOT）score(0-1).
Study: NCT04016220
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: first nebulization of 2ml of normal saline as placebo comparator in association with terbutaline and ippratropium bromide followed by repetitive nebulization of 5 mg of terbutaline with 2 ml of normal saline at 20, 40, 60 and 120 min.
Study: NCT00838435
Drug: sapropterin dihydrochloride
Normalized name: Sapropterin Dihydrochloride
DrugBank: Sapropterin (DB00360)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: A dose of 20 mg/kg will be administered dissolved in water or apple juice, based on subject's age and ability, and taken orally once daily with food.
Study: NCT04948164
Drug: sumatriptan 85mg and naproxen sodium 500mg
Normalized name: sumatriptan and naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subjects took 1 tablet of the study drug (each containing sumatriptan 85mg and naproxen sodium 500mg) within 1h of an acute migraine attack of mild severity, and if the headache progressed to moderate severity within 2 hours, they could take the remedial drug phenol chai (each containing acetaminophen 500mg and caffeine 65mg).
Study: NCT04948164
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: subjects were given one tablet of placebo within 1 h of an acute migraine attack with mild severity, and if the headache progressed to moderate severity within 2 hours, they were given the remedial drug phenol chai (each tablet contains acetaminophen 500 mg and caffeine 65 mg).
Study: NCT03837743
Drug: DUR-928 Topical Solution
Normalized name: Nitro-Dur Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical solution containing active drug
Study: NCT02205983
Drug: 1000 mg Acetaminophen
Normalized name: acetaminophen 1000 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: We are administering sublingual buprenorphine to healthy volunteers to measure its effects on the performance of a verbal task.
Study: NCT03285308
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo injected subcutaneously twice daily.
Study: NCT03283761
Drug: 5-FU 1200 mg/m^2 x 2 D
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I (N= 12), on day 1 and day 15-16 Stage II (N= 25),on day 1 and day 15-16
Study: NCT03283761
Drug: Leucovorin 400 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Stage I (N= 12),on day 1 and day 15 Stage II (N= 25), on day 1 and day 15
Study: NCT02029586
Drug: MB12066 200mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, 100mg bid
Study: NCT02029586
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration, 100mg bid
Study: NCT02299115
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Corticosteroid
Study: NCT01459562
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01442428
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Naproxen: 250 mg 3x daily for 2 weeks, then 2x daily for 1 week, then once daily for 1 week
Study: NCT01442428
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin placebo
Study: NCT00589329
Drug: erythromycin and metronidazole (antibiotics)
Normalized name: metronidazole and diloxanide
Approvals — FDA: no, EMA: no, PMDA: no
Description: Erythromycin 250 mg IV q 6 hours x 8 doses, followed erythromycin 250 mg tabs, 1 PO q 8 hours for five days.~Metronidazole, 1 gm IV loading dose followed by 500 mg IV q 12 hours x 4 doses, followed by metronidazole 500 mg tabs, 1 PO q 8 hours for five days
Study: NCT00589329
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV and pill placebo
Study: NCT00866190
Drug: SQ109
Normalized name: SQ109
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQ109 150 mg is an oval, coated, white, scored tablet. Dosages: 75 mg administered once daily for 14 days; 150 mg administered once daily on Days 1-5, 9, and 14; and 150 mg administered once daily for 14 days.
Study: NCT00866190
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is an oval, coated, white, scored tablet administered once daily for 14 days or on Days 1-5, 9, and 14.
Study: NCT00239044
Drug: Enteric-coated Mycophenolate sodium (EC-MPS)
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02912650
Drug: Ibuprofen 250 mg / Acetaminophen 500 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 caplets of Ibuprofen 250 mg / Acetaminophen 500 mg
Study: NCT02912650
Drug: Ibuprofen 250 mg
Normalized name: ibuprofen 250 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 caplets of Ibuprofen 125 mg
Study: NCT02912650
Drug: Acetaminophen 650 mg
Normalized name: acetaminophen 650 MG
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 tablets of Acetaminophen 325 mg
Study: NCT02912650
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 caplets of Placebo
Study: NCT00294463
Drug: Estradiol
Normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00294463
Drug: Estradiol + Medroxy Progesterone Acetate
Normalized name: ESTRADIOL/PROGESTERONE
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00525551
Drug: Placebo (NaCl)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mL 0.9% NaCl
Study: NCT00345657
Drug: Niacin Extended Release/Lovastatin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00635232
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo capsules once daily for 12 weeks
Study: NCT00635232
Drug: PS433540
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200 mg (2 x 100 mg capsules) once daily for 12 weeks
Study: NCT00635232
Drug: PS433540
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg (4 x 100 mg capsules) once daily for 12 weeks
Study: NCT00635232
Drug: PS433540
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800 mg (8 x 100 mg capsules) once daily for 12 weeks
Study: NCT00578669
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20mg once daily for 16 weeks
Study: NCT00319982
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator (double-blind allocation of study medication)
Study: NCT00758680
Drug: MK-1006
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-1006 capsules (10 mg and 20 mg) administered orally from 20 mg to 120 mg per dose over a multiple dosing period.
Study: NCT00758680
Drug: Comparator: Placebo comparator
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched MK-1006 placebo capsules (1 mg, 10 mg and 20 mg) administered orally over a multiple dosing period.
Study: NCT02565173
Drug: placebo BID
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo administered twice per day in both eyes for 12 weeks.
Study: NCT00943267
Drug: Endotoxin
Normalized name: Endotoxin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Endotoxin (4 ng/kg body weight) is given intrabronchially in one subsegment at t=0
Study: NCT00574912
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single dose of Placebo injected s/c at 8am and monitor blood glucose over 24 hours
Study: NCT00546364
Drug: Ixabepilone, 32 mg/m^2 + Capecitabine, 1000 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ixabepilone, 32 mg/m\^2, administered as a 3-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study: NCT00546364
Drug: Docetaxel, 75 mg/m^2 + Capecitabine, 1000 mg/m^2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Docetaxel 75 mg/m\^2 administered as a 1-hour IV infusion on Day 1 of a 21-day cycle plus capecitabine, 1000 mg/m\^2, self-administered on an outpatient basis twice daily by mouth on Days 1 through 14 (±2 days) of each 21-day cycle.
Study: NCT02304627
Drug: insulin 338 (GIPET I)
Normalized name: insulin isophane, human Injectable Suspension [Humulin I]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Each subject will be randomly allocated to a fixed treatment sequence of four single-dose administrations of oral insulin 338 in a GIPET® I tablet, administered on four separate dosing visits. The subjects will be dosed in the morning in the fasting state prior to four different post-dose fasting periods.
Study: NCT02578030
Drug: SHP465 12.5mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02578030
Drug: SHP465 25mg
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05896930
Drug: Rifampicin 35 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rifampicin 35 mg/kg once daily on days 1-14.
Study: NCT02636192
Drug: No Intervention
Approvals — FDA: no, EMA: no, PMDA: no
Description: This is an observational study and participants did not receive any intervention in this study.
Study: NCT02249312
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04642651
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in the control group receive single-shot femoral nerve block preoperatively using a mixture of 0.375% ropivacaine and normal saline, in a total volume of 20 ml.
Study: NCT00527865
Drug: DAS181
Approvals — FDA: no, EMA: no, PMDA: no
Description: DAS181 is formulated as dry powder and packaged in capsules containing DAS181. The delivered dose of DAS181 dry powder at each fill size is 0.5 mg, 1.0 mg, 2.25 mg, and 4.5 mg.
Study: NCT00527865
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Capsules containing 10.5 mg of lactose will be supplied as placebo.
Study: NCT02954263
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04445363
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose extension: Placebo
Study: NCT01980966
Drug: MHAA549A
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose
Study: NCT01980966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV dose
Study: NCT01293838
Drug: Cipralex®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Based on a starting rate of 5 mg/day, increased by 5 mg every 2 weeks to a maximum of 20 mg/day for weeks 7-16, each participant will receive up to:~* 10 mg tablets: 28~* 20 mg tablets: 84~Total for 30 participants:~* 10 mg tablets: 840~* 20 mg tablets: 2520~Continuation study for participants who respond to Cipralex - Across 12 weeks, each participant will receive up to:~\*20 mg tablets: 84~Total for continuation study for all participants (assuming a 60% response rate, N=18):~\*20 mg tablets: 1512
Study: NCT02312908
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill manufactured to mask clonazepam 0.5mg tablet
Study: NCT01071187
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00638027
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: matched tablets bid
Study: NCT00293254
Drug: Comparator: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo p.o. b.i.d. with optimized background therapy. Treatment period of 48 weeks.
Study: NCT00822406
Drug: homeopathic medicine
Normalized name: Homeopathic medicine
Approvals — FDA: no, EMA: no, PMDA: no
Description: individualized homeopathic medicine
Study: NCT00822406
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo - 6 months
Study: NCT00193466
Drug: CAMPTH-1H
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00039026
Drug: AC2993
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 4 weeks / AC2993 5mcg (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT00039026
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Lead In (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 4 weeks / Placebo (0.02 mL) for 26 weeks - All are subcutaneously injected twice daily
Study: NCT05256524
Drug: The effect of LMWH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Quantified by aFXa-levels
Study: NCT04473911
Drug: CYCLOPHOSPHAMIDE
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ◦Cyclophosphamide predetermined dose, predetermined number of times in Given in pre-stem cell Regimen #1 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Study: NCT04473911
Drug: RGI-2001
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV, predetermined dose, weekly to 6 total doses
Study: NCT04473911
Drug: CYCLOPHOSPHAMIDE
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ◦Given in Post Stem Cell cycle of Regimen #1 and #2 Cyclophosphamide predetermined dose, predetermined number of times in cycle, intravenous infusion
Study: NCT02187055
Drug: Tofacitinib with methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily, oral for 12 months Methotrexate (previous stable dose 15-25 mg) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Study: NCT03202979
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral administration of placebo oral solution (10 drops) three times a day, for 8-week treatment.~After the 8-week treatment period, patients will receive placebo oral solution three times a day for 1-week tapering period in double blind conditions.
Study: NCT00848107
Drug: treprostinil diethanolamine
Normalized name: treprostinil 1 MG (as treprostinil diethanolamine) 12 HR Extended Release Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: sustained release tablet; BID dosing; up to 16 mg BID
Study: NCT03627520
Drug: [14C]Sulfatinib
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg Sulfatinib with 100 µCi \[14C\]
Study: NCT04509882
Drug: bear bile pill
Normalized name: bile salts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bear bile pill (15 pills) taken orally three times a day after meals with water.
Study: NCT04509882
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo(15 pills) taken orally three times a day after meals with water.
Study: NCT02187055
Drug: Tofacitinib without methotrexate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tofacitinib 5 mg twice daily, oral for 12 months Placebo for methotrexate (previous stable dose) every week, oral for 12 months Placebo for adalimumab every other week, subcutaneous for 12 months
Study: NCT02627248
Drug: Huaier Granule
Approvals — FDA: no, EMA: no, PMDA: no
Description: 20g tid, orally
Study: NCT02627248
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 600 mg/m² ivdrip, d2 for TEC regimes
Study: NCT01783548
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02923986
Drug: BP1001 (varying dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1001 (varying dose)
Study: NCT02923986
Drug: BP1001 (fixed dose)
Approvals — FDA: no, EMA: no, PMDA: no
Description: BP1001 (fixed dose)
Study: NCT03682224
Drug: Bupivacaine-Epinephrine
Normalized name: bupivacaine-epinephrine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bupivacaine-Epinephrine 0.25%, 1:200,000 (Marcaine with epinephrine), administered subcutaneously at port site
Study: NCT00894101
Drug: [F-18] FLT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mCi \[F-18\] FLT and 10 mCi \[F-18\] FDG will be used for PET imaging.
Study: NCT01635218
Drug: Individualized homeopathic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of the individualized homeopathic remedy in C-potency was dissolved in a 60 ml bottle of 30% alcohol-distilled water:15 drops PO two times per day following agitation plus fluoxetine-dummy loaded PO daily during 6 weeks. The homeopathic remedy could be changed at every follow-up (week 4) according to patient´s symptoms.
Study: NCT01635218
Drug: Fluoxetine
Normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 20 mg per day PO during 6 weeks plus individualized homeopathic dummy-loaded (60 bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic dummy-loaded was repeated at week 4.
Study: NCT01635218
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoxetine placebo (capsules containing sucrose microgranules) PO daily during 6 weeks plus individualized homeopathic placebo (60 ml bottle of 30% alcohol-distilled water: 15 drops PO two times per day following agitation). The individualized homeopathic placebo was repeated at week 4.